

### Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma

S. Saesoo, S. Sathornsumetee, P. Anekwiang, C. Treetidnipa, P. Thuwajit, S. Bunthot, W. Maneeprakorn, Lionel Maurizi, H. Hofmann, Ruktanonchai Uracha Rungsardthong, et al.

#### ▶ To cite this version:

S. Saesoo, S. Sathornsumetee, P. Anekwiang, C. Treetidnipa, P. Thuwajit, et al.. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. Colloids and Surfaces B: Biointerfaces, 2018, 161, pp.497-507. 10.1016/j.colsurfb.2017.11.003 . hal-02163452

### HAL Id: hal-02163452 https://hal.science/hal-02163452

Submitted on 14 Mar 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed
2	as a novel theranostic agent for central nervous system lymphoma
3	
4	S. Saesoo S <sup>(1)</sup> , S. Sathornsumetee <sup>(2,5)</sup> , P. Anekwiang <sup>(2)</sup> , C. Treetidnipa <sup>(2)</sup> ,
5	P. Thuwajit <sup>(2,4)</sup> , S. Bunthot <sup>(1)</sup> , W. Maneeprakorn <sup>(1)</sup> , L. Maurizi <sup>(6)</sup> , H. Hofmann <sup>(7)</sup> ,
6	Ruktanonchai Uracha Rungsardthong <sup>(1)</sup> , N. Saengkrit <sup>(1)</sup>
7	
8	(1) National Nanotechnology Center (NANOTEC), National Science and Technology
9	Development Agency (NSTDA), Pathumthani 12120, Thailand
10	(2) NANOTEC-Mahidol University Center of Excellence in Nanotechnology for Cancer
11	Diagnosis and Treatment and Departments of (3) Radiology, (4) Immunology and (5)
12	Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University 2 Wanglang Road,
13	Bangkoknoi, Bangkok 10700, Thailand
14	(6) Laboratoire Interdisciplinaire Carnot de Bourgogne, UMR 6303 CNRS—Université
15	Bourgogne Franche-Comté, BP 47870, F-21078 Dijon cedex, France
16	(7) Powder Technology Laboratory, Ecole Polytechnique Fédérale de Lausanne (EPFL),
17	1015 Lausanne, Switzerland.
18	
19	1. Introduction
20	Despite advances in the understanding of genetic and molecular abnormalities relating
21	to cancer, and in development of new therapies, the prognosis of patients with primary central
22	nervous system lymphoma (PCNSL) remains poor when compared to other lymphoma types
23	(median survival 3-5 years) [1]. For immunocompromised patients, such as those with AIDS
24	or in cases of organ transplantation, median survival times are often markedly reduced
25	(typically less than 1 year) [2]. Due to this, and the rising incidence of PCNSL over the past
26	decades there is a need to develop new diagnostic and therapeutic strategies which are
27	applicable to these patients, including the wider population [3].

28 PCNSL accounts for 3-5% of primary brain tumors in adults, and occurs with an 29 incidence of 5 per 1,000,000 people in developed countries [1]. Most (> 95%) PCNSL cases 30 are of the diffuse large B-cell type. Genetic abnormalities in PCNSL cells are distinct from those occurring in other lymphomas; this factor may relate to observed differences in prognosis 31 32 and treatment response [4]. Non-invasive imaging studies such as magnetic resonance imaging (MRI) and positron-emission tomography (PET) scans can support an initial diagnosis of 33 PCNSL, however confirmation usually requires a stereotactic biopsy. Alternatively, cytology 34 of cerebrospinal fluid, or ocular vitreous, may confirm diagnosis in 20-30% of patients. 35 36 Diagnosis of AIDS-associated PCNSL represents an important challenge in clinical practice. Radiographic findings of PCNSL in immunocompromised patients are often indistinguishable 37 from infections, particularly toxoplasmosis. In these cases, biopsies are often deferred until the 38 empiric treatment for toxoplasmosis fails, causing delays in diagnosis. Therefore, non-invasive 39 diagnostic approaches, such as neuroimaging probes, for PCNSL in AIDS patients may hasten 40 diagnosis allowing early treatment. High-dose methotrexate (HD-MTX)-based chemotherapy 41 regimens are the standard treatment for PCNSL [5], and these combined with other 42 chemotherapies (cytarabine, procarbazine, vincristine, or ifosfamide) have been shown to 43 44 provide superior results in some cases, although the higher toxicity is a serious issue. RTX, a 45 monoclonal antibody against CD20, has demonstrated promising activity as a single agent in PCNSL [6], despite the inherent limitation of such a large molecule in traversing the blood-46 47 brain barrier [7, 8]. Employing nanoparticles as a carrier for RTX may help overcome this challenge, and result in increased efficacy in PCNSL treatment. 48

49 The blood-brain barrier represents a major obstacle for drug delivery to the CNS [9, 10]. The use of a small lipophilic carrier, such as a nanoparticle system, may overcome this 50 problem, with nanoparticles allowing for improved drug delivery metrics as well as diagnostic 51 and monitoring capabilities. This emerging molecular platform, "theranostics" [11], employs 52 53 nanoparticle systems based on liposomes [12], micelles [13], and dendrimers [14] to protect drugs and deliver them to targets in a controlled manner. In addition, they can be decorated 54 with "molecular antennae" such as antibodies or aptamers on their surface to allow target 55 specificity. Imaging probes are an important group of theranostic particles: these can be 56 detected in vivo through various imaging modalities [15]. Superparamagnetic iron oxide 57 nanoparticles (SPIONs) and radioisotopically labelled nanoparticles are common imaging 58 probes detectable by magnetic resonance imaging and positron emission tomography, 59 respectively. Among the various nanoparticle classes available, liposomes have shown real 60

promise in the treatment of brain disorders [16-18], having been shown to enhance the delivery of neuroprotective agents to the peri-infarct area in experimental ischemic stroke models [17, 18]. In this study, we fabricated nanoparticles consisting of liposome containing SPIONs decorated with RTX, and subsequently evaluated their imaging and targeting abilities, including therapeutic potency, in a BBB model of PCNSL.

#### 66 2. Materials and methods

#### 67 2.1 Materials

Soybean lecithin (Soya Phosphatidylcholin; PC) was purchased from Degussa 68 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-(Hamburg, Germany). 69 [amino(polythylene glycol 2000)] (DSPEG-PE), and 1,2-dioleoyl-sn-glycero-3-70 phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide] (MPB-PE, linker) 71 were 72 purchased from Avanti Polar Lipids, Inc (Alabama, USA). Cholesterol was also obtained from Avanti Polar Lipids, Inc (Alabama, USA). Polysorbate 80 (Tween 80) was obtained from 73 Sigma-Aldrich (Saint Louis, MO, USA). Phosphate buffered saline (pH 7.4) (PBS; containing 74 75 137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>; 2 mM KH<sub>2</sub>PO<sub>4</sub>), and Triton X-100 were 76 obtained from Merck (Merck Millipore, Darmstadt, Germany). Anti-CD20 (RTX) was purchased from Roche (Basel, Switzerland). Roswell Park Memorial Institute media (RPMI 77 78 1640) was from GIBCO Invitrogen (New York, USA). Fetal bovine serum (FBS) was obtained from Biochrom AG (Berlin, Germany). Trypsin-EDTA, L-glutamine, penicillin G sodium, 79 80 streptomicin sulfate, and amphotericin B were obtained from Invitrogen Corp. (New York, USA). MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was purchased 81 82 from GIBCO Invitrogen (NY, USA). Dimethylsulfoxide (DMSO) was procured from Sigma-83 Aldrich, Inc, (Dorset, UK). The Annexin V-FITC Apoptosis Detection Kit was obtained from 84 NeXins Research BV (Rotterdam, the Netherlands). Distilled water was generated using an ELGA system (PureLab Ultra, Illinois, USA). Z138C and Granta519 lymphoma cell lines were 85 graciously provided by Dr. Siwanon Jirawatnotai (Bangkok, Thailand). SPIONs-PVA 86 nanoparticles were kindly provided by Prof. Heinrich Hofmann and Dr. Lionel Maurizi (EPFL, 87 Switzerland). These particles were synthesized from maghemite ( $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>), affording SPIONs 88 having a diameter less than 20 nm. All SPIONs were coated with PVA (Polyvinyl alcohol) for 89 stabilization [19] and called SPION-PVA. 90

#### 91 **2.2 Lymphoma cell cultivation**

Granta and Z138C cell lines were cultured in RPMI 1640 medium. The medium was supplemented with 10% FBS containing 0.1 mM non-essential amino acids (100  $\mu$ g/ml Lglutamine, 100  $\mu$ g/ml streptomycin and 100 U/ml penicillin). Cells were grown and propagated in 75 ml T-flasks, and incubated at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. The medium was changed every other day.

#### 97 2.3 Preparation of liposomes and conjugation of RTX

A series of liposome nanoparticles were prepared by conventional thin film hydration, 98 which involved the mixing of PC, DSPEG-PE, Tween 80 and MPB-PE (linker) in various 99 proportions, as indicated in Table 1. Each mixture was then dissolved in chloroform-diethyl 100 ether (3:1 v/v, 10 ml), and upon solvent removal by rotary evaporation at 25°C under 50-100 101 kg/cm<sup>2</sup> nitrogen flow thin lipid films were obtained. After drying, lipid films were rehydrated 102 103 with 0.2 mg<sub>Fe</sub>/ml of SPION-PVA dissolved in PBS (pH 7.4), and re-suspended with shaking at room temperature. Particle sizes of all liposome samples were reduced using a discontinuous 104 105 extruder (Liposo-Fast<sup>TM</sup>-10, Avestin Inc, Ottawa, Canada) operating at 200 bar pressure over 15-20 cycles, through a 200 nm pore size polypropylene membrane (Millipore GmbH, 106 Eschborn, Germany). The SPIONs-PVA loaded liposomes were purified by centrifugation 107 (TomyMX-301, Tokyo, Japan) at 10,000 rpm for 30 min, prior to collection. The obtained 108 pellets were re-suspended in PBS (pH 7.4) buffer for measuring of SPION entrapment. 109 Additionally, in order to obtain an optimized formulation for BBB delivery, the following 110 liposome series were initially prepared: liposome (Lip), Lip/PEG, Lip/Tween80, 111 Lip/PEG/Tween80, Lip/PEG/Tween80 and Lip/PEG/Tween80/RTX. 112

113 Immobilization of RTX was performed via chemical conjugation. Thiolated RTX was firstly prepared by mixing RTX with 2-iminothiolane at 25°C for 30 min. The conjugation of 114 115 RTX and liposomes was achieved via the coupling of thiolated RTX and MPB-PE onto the liposome surface. This required gradual addition of MPB-PE-liposomes into the freshly 116 prepared thiolated RTX, followed by incubation of the solution at 4°C overnight under nitrogen 117 atmosphere, with continuous stirring. The resultant RTX conjugated liposomes were purified 118 by ultracentrifugal sedimentation at 60,000 rpm for 90 min, and the obtained pellets were re-119 suspended and washed twice with PBS buffer (pH 7.4). 120

#### 121 2.4 Morphology and physicochemical characterization of liposomes

The morphology of liposomes was investigated using transmission electron microscopy (TEM). Samples were prepared by placing 5 µl of liposome solution onto a 200-mesh carbon copper grid (EMS Equipment, Berks, UK). After 10 min, the droplet was removed from the edge of the grid using filter paper. Samples were dried by standing at room temperature prior to imaging: TEM (model JEM 2010; JEOL, Peabody, MA) accelerating voltage 120 KV, 50 K magnification.

Hydrodynamic diameter, polydispersity index (PDI) and zeta potential of liposomes were determined by dynamic light scattering (DLS) (NanoZS4700 nanoseries, Malvern Instruments, Malvern, UK). All samples were diluted with 1 ml of filtered distilled water prior to measurements being taken to eliminate viscosity effects caused by the ingredients. Hydrodynamic diameter (based on volume measurement), PDI and zeta potential were obtained from the average of three measurements at 25°C. The refractive indices of liposomes and water were set at 1.42 and 1.33, respectively.

#### 135 **2.5 Determination of SPIONs-PVA encapsulation**

136 The encapsulation of SPIONs-PVA within liposomes was quantified using the Prussian 137 Blue assay, where samples were diluted for preparation of a calibration curve (at least 3 serial dilutions required). Particle iron concentrations ([Fe] in mg Fe mL<sup>-1</sup>) were measured through a 138 colorimetric assay. SPIONs-PVA were first digested by incubation overnight with an equal 139 volume of 6M HCl. Then, 25 µl of digested particles was mixed with 50 µl of 5% w/v 140 141 K<sub>4</sub>Fe(CN)H<sub>2</sub>O in water (freshly prepared and covered with aluminium foil). The sample was then shaken continuously for 15 min, followed by measurement of the iron content, which 142 measured from the reaction between  $K_4[Fe(CN)_6]$  and  $Fe^{3+}$  to give an intense blue product 143 (Prussian blue, Fe<sub>4</sub>[Fe(CN)<sub>6</sub>]<sub>3</sub>) whose optical density was measured at 690 nm using a 144 145 microplate spectrophotometer (SpectraMAX2, Molecular Devices GmbH, CA, USA). The 146 encapsulation efficiency was calculated using the equation below.

147 
$$\% EE = \frac{Total \ amount \ of \ determined \ SPION}{Initial \ amount \ of \ SPION \ loading} \times 100$$

#### 148 **2.6 MTT assay**

To evaluate the toxicity of SPIONs-PVA loaded liposomes, cells were plated in 96well plates, each containing 90 μl of RPMI with 10% fetal bovine serum at a density of 8,000

151 cells/well. When the cultures had reached confluency (typically 24 h after plating) they were exposed to SPIONs-PVA loaded liposomes at SPIONs-PVA concentrations of 0.0005, 0.001, 152 0.0025, 0.005, 0.01 or 0.02 mg<sub>Fe</sub>/ml. The treated cells were then incubated for 24 h at 37°C in 153 a CO<sub>2</sub> atmosphere. After washing twice with PBS (pH 7.4), 25 µl of MTT solution was added 154 into each well, followed by further incubation (4 h). The medium was then removed and 155 replaced with 100 µl of dimethylsulfoxide, followed by further incubation for 30 min at 37°C. 156 Following this, the absorbance of the colored solution was measured at 550 nm using a 157 microplate reader (SpectroMAX, California, US), and the percentage cell viability was 158 calculated using equation and compared with that of the control. 159

% Cell survival = 
$$\frac{(Ab_{550} sample - Ab_{550} control)}{Ab_{550} control} \times 100$$

160

161

where  $Ab_{550}$  = absorbance value at 550 nm

#### 162 **2.7 Stability of liposomes**

Liposome samples were stored in PBS (pH 7.4) buffer at 4°C, and 25°C for prolonged periods to gauge their stability. Samples were taken periodically at intervals of 1, 3 and 4 months and liposome stability monitored using particle diameter, polydispersity index (PDI) and zeta potential measurements. Each measurement was performed in triplicate, and expressed as an average value.

#### 168 2.8 Magnetization analysis by VSM

The magnetic properties of SPIONs, SPIONs-PVA and SPIONs-PVA loaded into Lip,
Lip/PEG, Lip/Tween80 and Lip/PEG/Tween80/linker liposomes were assessed using vibrating
sample magnetometry (VSM, LakeShore Model 7404, USA). For this, all samples were freezedried in liquid nitrogen and lyophilized under vacuum. The magnetic field was applied at 10
kOe in all measurements.

174 **2.9 Cellular uptake of liposomes** 

Internalization of liposomes was monitored by confocal laser scanning microscopy
(CLSM), and flow cytometry. To monitor liposome uptake, Lip/PEG-PE and Lip/PEGPE/RTX were labeled with Dil dye tracer (Invitrogen, Paisley, UK) at a ratio of 1:1000 v/v.
Granta and Z138C cells (1×10<sup>6</sup> cells) were seeded onto sterilized glass coverslips and allowed

179 to adhere overnight in a 6-well plate. At transfection, Dil labeled liposomes were added to the cells at a concentration of 0.4 mg/ml, which corresponds to the IC<sub>20</sub> value indicating 80% cell 180 viability. For CLSM, cell and liposome particles were incubated together for 2 h at 37°C under 181 an atmosphere of 5% CO<sub>2</sub>. Cells were then washed twice with PBS (pH 7.4), fixed with 4% 182 w/v paraformaldehyde for 10 min, and then twice washed again with PBS (pH 7.4). For cellular 183 DNA staining, Hoechst dye (Molecular Probes, OR, USA) was diluted in PBS (pH 7.4) buffer 184 at a ratio of 1:1500 v/v, then incubated with the cells for 10 min. Cells were washed twice with 185 PBS pH 7.4 after staining then observed under confocal microscope. Images were acquired 186 187 using a laser scanning confocal microscope (Nikon, ECLIPSE Ti-Clsi4 Laser Unit, Japan), using the 60 objective lane. SPIONs-PVA detection was achieved by reflecting laser scanning, 188 with laser excitation at 488 nm. 189

Flow cytometry was employed to quantify cell internalization of liposomes. Cells were 190 191 cultivated in 6-well plates until growth levels reached 80% confluence. After washing with PBS, cells were incubated with Dil-labeled SPION-PVA loaded liposomes (phosphatidyl 192 193 choline: Dil 1:500 w/w) at a concentration corresponding to the IC<sub>20</sub> value. Cellular internalization of liposomes was quantified with time: after incubation for 30 min, 1, 2 and 4 h 194 195 unbound liposomes were removed by washing three times with PBS. At each time point, internalization signals were analyzed using a flow cytometer (BD FACS Calibur™, BD 196 biosciences, CA, USA) at excitation and emission wavelengths of 488 and 600 nm, 197 respectively. 198

#### 199 2.10 Apoptosis assay

200 Cells treated with liposomes were double stained with AnnexinV-FITC (AV-FITC) and propidium iodide (PI) to detect apoptotic, and necrotic cells. AV-FITC/PI co-labeling was 201 performed according to the standard protocol as recommended by the manufacturer (BD 202 Pharmingen<sup>TM</sup>, BD Biosciences, San Jose, CA, USA). Cells were seeded in a 6-well plate at a 203 density of  $1 \times 10^6$  cells/well, and were allowed to attach for 24 h. After medium refreshment, 204 cells were exposed to either RTX, Lip, Lip/PEG-PE/SPIONs-PVA, Lip/PEG-205 PE/Tween80/SPIONs-PVA or Lip/PEG-PE/Tween80/SPIONs-PVA/RTX at a concentration 206 corresponding to the IC<sub>20</sub> for 24 h at 37°C. Cells were then detached using trypsin–EDTA 207 solution, re-suspended in fresh medium, and centrifuged at 1,000 rpm for 5 min. The obtained 208 pellets were re-suspended in PBS (pH 7.4), centrifuged for a further 5 min (1,000 rpm), and 209 then collected and re-suspended in AnnexinV binding buffer. All samples were stained with 5 210

µl of AV-FITC and 10 µl of PI, and then incubated for 15 min in the dark at 25°C. After addition of 250 µl of AnnexinV binding buffer to each, cells were analyzed using flow cytometry (BDFACS Calibur<sup>TM</sup>, BD biosciences, San Jose CA, USA). The flow cytometer was equipped with filters capable of detecting PI at excitation/emission wavelengths of 520/570 nm, while FITC was detectable at excitation/emission wavelengths of 485/535 nm. Results are presented in a dot plot of AV-FITC versus PI with quadrant gating. The percentage apoptosis in cells was determined using the FACSDiva software package.

#### 218 2.11 *In vitro* model BBB of PCNSL for permeability and therapeutic testing

Permeability of the BBB can be gauged by measuring the transendothelial electrical 219 resistance (TEER), which affords a direct relation to its structural integrity. An in vitro co-220 culture model of BBB was set up according to protocol of Imamura et al. [20]. For this, bEnd3 221 cells were seeded onto 0.4 µm pore size polyester membrane inserts (density of 20,000 222 cells/insert) contained in a 12-well plate transwell tray (Corning, NY, USA). The cells were 223 allowed to grow on the membrane for 8 days, with the DMEM medium being changed every 2 224 days. With this system, the drug targeting, and therapeutic effect, of RTX and liposomes on B 225 cell lymphoma cells was evaluated: for this, Granta cells were seeded at the bottom of the 226 culture dish and were allowed to grow for 4 days. After this time the TEER values were 227 monitored until they reached 140-150  $\Omega$ .cm<sup>2</sup> (approximately 7-10 days), after which the model 228 ready for use in testing. Testing involved loading either free RTX, 229 was Lip/PEG/Tween80/SPIONs-PVA or Lip/PEG/Tween80/SPIONs-PVA/RTX into separate 230 apical compartments of the co-culture model, with final concentrations of RTX (17.5 µg/ml) 231 coinciding with that of the IC<sub>50</sub> of free RTX against Granta cells. 232

Determination of RTX concentrations in the membrane model was undertaken at set time points (1, 2, 3, 5, 7 and 24 h) using the PK ELISA Kit (MyBioSource, CA, USA), with harvesting of Granta cells at these times allowing evaluation of therapeutic effects. During the 24 h period, the TEER value was also monitored using a Millicell ERS-2 Voltohmmeter (Millipore, MA, USA) for analysis of the permeability efficiency.

238 3. Results and discussion

# 3.1. Morphology and physicochemical characterization of liposomes and encapsulation efficiency

241 TEM was employed to observe the morphologies of SPIONs-PVA, bare liposomes and SPIONs-PVA loaded liposomes. While all samples were dehydrated for imaging, the 242 nanoparticles could be observed as having discrete spherical shapes (Fig. 1). SPIONs-PVA 243 showed a narrow size distribution (< 20 nm) (Fig. 1a). Liposomes fabricated in the absence of 244 added nanoparticles are spherical in shape but show slight deformations (Fig. 1b and c), while 245 SPIONs-PVA loaded liposomes exhibit a more pristine spherical profile as a result of tight 246 cargo packing resulting in size reduction, and enhanced stability, under TEM voltage exposure 247 (Fig. 1d and e). 248

249 Average hydrodynamic diameters, PDI and zeta potentials for bare, and SPIONs-PVA 250 loaded liposomes were obtained using DLS, with data summarized in Table 1. In the absence 251 of cargo, the diameters of Lip (control), Lip/PEG, Lip/Tween80, Lip/PEG/Tween80 and Lip/PEG/Tween80/RTX liposomes were  $141.9 \pm 1.0$  nm,  $169.9 \pm 11.3$  nm,  $161.0 \pm 12.6$  nm, 252 253  $157.2 \pm 9.1$  nm and  $182.0 \pm 6.3$  nm, respectively. Consistent with TEM results, loading of SPIONs-PVA induces liposome contraction, an effect perhaps related to strong hydrophilic 254 255 interactions between liposome phospholipids and the PVA coating of SPIONs, which would underpin their stability under TEM conditions [21]. The PDI index of all liposomes, being in 256 257 the range of 0.1 to 0.3, is indicative of homogeneity and narrow size distribution, which is again consistent with findings from TEM. Loading of SPIONs-PVA results in liposome surface 258 charges becoming more negative, with these having zeta potentials ranging from -2.3 to -9.0 259 mV, depending on liposome composition. This result probably relates to the interaction of the 260 SPIONs-PVA surface with PC in the liposome membrane. Surface modification of liposomes 261 via RTX conjugation also affected their physicochemical properties: the zeta potential of bare 262 liposome (Lip) was -0.1 mV, whereas that of Lip/PEG/Tween80/RTX became more negative 263 (-7.2 mv) (Table 1). 264

SPIONs-PVA liposome loadings were quantified using the Prussian Blue assay as described in section 2.5. From this data encapsulation efficiencies (%EE) for each liposome formula were obtained (Table 1). A notable effect resulted from inclusion of Tween 80 into the liposome structure: this resulted in remarkably higher entrapment (higher %EE) of SPIONs-PVA relative to other liposome formulations. It is assumed that Tween80 incorporation into the film helps to promote liposome stability, and prevents egress of SPIONs-PVA during preparation [22].

#### 272 **3.2. Liposome cytotoxicity**

The toxicity of SPIONs-loaded liposome formulas was analyzed using Z138c as a 273 lymphoma cell model, in order to evaluate their safety. All liposomes showed concentration-274 dependent cytotoxicity, although no significant effects to cells were evident on exposure to 275 bare SPIONs-PVA (Fig. 2). Liposome solutions having SPIONs-PVA concentrations less than 276 277 0.0025 mg/ml were considered safe, as exposure to these resulted in greater than 80% cell survival rates. Higher cytotoxicities were found for Tween80 fabricated liposomes; addition of 278 Tween 80 may enhance cellular uptake via ApoE ligand-mediated endocytosis [23]. However, 279 for these systems cell viabilities are still in the acceptable range although optimization of 280 281 liposome concentrations needs to be addressed to further their use in theranostic applications.

#### 282 **3.3. Stability of liposomes**

In this study, we determined the stability of liposomes on storage at 4°C and 25°C. 283 Particle diameter, PDI and zeta potential of Lip, Lip/PEG/Tween20/SPIONs and 284 Lip/PEG/Tween20/SPIONs/RTX were measured periodically (1, 3 and 4 months) after storage 285 (Table 2). In regards to diameter and zeta potential of colloidal liposomes, for both 286 temperatures all formulations were stable for up to 3 months. Liposome stability could be 287 prolonged for a further month at 4°C, in contrast to results at 25°C which show dramatic 288 changes in zeta potential during the 4<sup>th</sup> month of storage. This would indicate aggregation of 289 liposome particles over time, as reflected by an increase in particle diameter. However, 290 diameter increases, and zeta potential changes are less marked in Tween80 supplemented 291 292 liposomes, the enhanced stability of these being consistent with previous work highlighting the use of Tween80 as a non-ionic surfactant to improve liposome stability [22]. 293

#### **3.4.** Magnetic property analysis by vibrating scanning magnetometry (VSM)

Vibrating scanning magnetometry (VSM) was performed to confirm the 295 296 superparamagnetic properties of SPIONs-loaded liposomes. Figure 3 highlights magnetization curves, and saturation magnetization of SPIONs-PVA (0.5 mg/ml), and the series of liposomes: 297 Lip, Lip/PEG/SPION-PVA, Lip/PEG/Tween80/SPION-PVA, and Lip/PEG/Tween80/SPION-298 PVA/RTX. The saturation magnetization values of naked SPIONs were also determined, as a 299 positive control. The hysteresis curves of SPIONs-loaded liposomes showed an absence of 300 remanence, and this, in conjunction with the magnetization on average being zero, indicates 301 that the SPIONs exhibit superparamagnetic behavior. Although the saturated magnetization 302 value of naked SPIONs was found to be 28.9 emu/g, coating with PVA results in a drastic 303 magnetization decrease (1.5 emu/g). This effect has been noted previously, for example in PVA 304

coated magnetite magnetic [24], and silica coated magnetic nanoparticles [25]. For SPIONs-PVA loaded liposomes, the saturated magnetization values were in range of 0.2-0.5 emu/g (Fig. 3). This magnetization range corresponds to those of SPIONs obtained from maghemite ( $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>), the values of which are thought to be lower than those from magnetite (Fe<sub>3</sub>O<sub>4</sub>) [26]. These findings are a preliminary step in the characterization of these systems, however for actual implementation as theranostics further optimization of the magnetization value is necessary.

#### 312 **3.5.** Liposome cellular internalization and uptake

Cellular uptake, and distribution of liposomes and SPIONs-PVA was monitored by 313 confocal microscopy. Cells were treated with Lip/PEG/Tween80/SPIONs-PVA and 314 Lip/PEG/Tween80/SPIONs-PVA/RTX, according to the protocol described in section 2.9. At 315 2 h post incubation, SPIONs-PVA were detectable within cells (as shown in green) by 316 reflecting laser scanning (excitation at 488 nm), while liposome nanoparticles appear red due 317 to the presence of Dil (Fig. 4). Z-stack imaging analysis confirmed internalization of the 318 particles within the liposomes (data not shown). Confocal imaging indicated that signal 319 intensities of Lip/PEG/Tween80/SPIONs-PVA/RTX were significantly higher than those of 320 Lip/PEG/Tween80/SPIONs-PVA, both in Z138c and Granta cell lines (Fig. 4a and 4b). These 321 results imply that conjugation of RTX promotes liposome internalization and provides 322 evidence supporting that binding of RTX occurs selectively on CD-20 presenting lymphoma 323 324 cells.

To confirm targeting of RTX conjugates with CD-20 lymphoma cells, we then 325 326 monitored the cellular uptake of liposomes quantitatively by flow cytometry. Lip/PEG/Tween80/SPIONs-PVA and Lip/PEG/Tween80/SPIONs-PVA/RTX were incubated 327 with cultured cells, and uptake was monitored at times of 30 min, 1, 2, and 4 h. Histograms 328 329 obtained from flow cytometry analysis indicate that cellular internalization of liposomes is time-dependent (Fig. 5). While liposome uptake takes place within 0.5 h-post incubation, the 330 signal intensities of Lip/PEG/Tween80/SPIONs-PVA and Lip/PEG/Tween80/SPIONs-331 PVA/RTX were not equal, and were observed to change during the incubation period. In both 332 Granta and Z138c cell lines the signal intensity from Lip/PEG/Tween80/SPIONs-PVA/RTX 333 proved higher than that resulting from Lip/PEG/Tween80/SPIONs-PVA, which confirmed that 334 RTX functions as a specific antibody for selective binding to anti-CD20 receptors in lymphoma 335 cells. 336

#### 337 **3.6.** Apoptosis induction by RTX conjugated liposomes

RTX is a mainstay in therapies for a broad variety of B-cell malignancies [27, 28]. It 338 induces direct apoptosis through binding to CD20 on the surface of lymphoma cells. In order 339 to verify targeting, and therapeutic effects of Lip/PEG/Tween80/SPIONs-PVA/RTX, 340 annexinV-FITC/PI staining was employed to monitor RTX-induced cell death. For this, Granta 341 and Z138c cell lines were incubated with free RTX (7.9 µg/ml), bare liposomes (Lip), 342 Lip/PEG/SPIONs-PVA, Lip/PEG/Tween80/SPIONs-PVA and Lip/PEG/Tween80/SPIONs-343 PVA/RTX (at the IC<sub>20</sub> concentration) for 24 h at 37°C. Cells were then removed to determine 344 345 the degree of apoptosis using flow cytometry. In Fig. 6a and 6b, the lower right quadrant shows annexin positive cells (early apoptotic stage) and the upper right quadrant shows annexin and 346 PI positive cells (late stage apoptosis). Lip/PEG/Tween80/SPIONs-PVA/RTX induced 347 apoptosis by a significantly high degree in both Granta and Z138c cells (by 65.4% and 43.1%, 348 349 respectively), while free RTX resulted in lower levels of apoptosis induction (18.3% and 16.7% in Granta and Z138c cells, respectively). These results not only suggest that RTX exerts 350 351 therapeutic effects, but also illustrates the effect of liposome conjugation on the efficacy of apoptosis induction. The presence of RTX on the surface of liposomes allows for advantageous 352 353 binding with the target cells in addition to facilitating its cellular uptake, in line with its role as 354 a therapeutic agent. Notably, treatment of cells with RTX-free liposomes results in less than 10% apoptosis, suggesting that the carrier itself is relatively benign. 355

#### 356 **3.7 Transport of RTX across the BBB model**

In order to demonstrate transportation of our formulated liposome across the BBB, an 357 358 in vitro BBB model was established according to a previous protocol [20]. During the investigation (over 24 h), TEER values of the cell control were constantly maintained at 140-359  $\Omega.cm^2$ . After model development, it was loaded with free RTX 360 150 and Lip/PEG/Tween80/SPIONs-PVA/RTX, and these samples were allowed to pass the cell 361 monolayer for a set time period. The extent of transported RTX was quantified by ELISA 362 measurements at set time points, up to 24 h post-loading. The results revealed that free RTX is 363 not readily transported through the BBB membrane, although liposomes act as a facile delivery 364 system promoting cross-barrier transport (Fig. 7). Tween 80 may play a crucial role in 365 fabrication of this delivery system: previous work has highlighted its binding with ApoE on 366 bEnd3 endothelial cells [23]. Concentrations of RTX detected across the membrane were time-367 dependent and were consistent with TEER values, except for the period at 5 h post incubation 368

where the level of permeable RTX may have been affected by the charge on the bEnd3endothelial membrane.

#### 371 **3.8 Evaluation of drug targeting therapeutic effect**

As the ability of RTX to be transported across the BBB is a major factor dictating its 372 therapeutic effects, the capacity of RTX to target Granta cells was evaluated in the BBB model 373 by analysis of cellular viability. Free RTX and Lip/PEG/Tween80/SPIONs-PVA/RTX were 374 375 loaded onto the BBB model, at an RTX concentration corresponding to the IC<sub>50</sub> (17.5  $\mu$ g/ml). At 24 h post incubation, Granta cells located at the basal layer were collected to evaluate cell 376 viability, in comparison with the control. The results shown in Fig. 8 indicate that, during the 377 incubation period, no effects relating to free RTX were observed. In contrast, exposure to RTX-378 conjugated liposomes resulted in noticeable toxic effects after 5 h, with the level of toxicity 379 380 being time-dependent. This result confirmed that effective delivery of RTX across the BBB requires a delivery system, and accordingly modified liposomes may be considered as an 381 appropriate vehicle for promoting therapeutic effects. 382

#### 383 **4.** Conclusion

Diagnosis of primary CNS lymphoma currently relies on pathology derived from a brain biopsy, which carries significant risk. Non-invasive neuroimaging protocols that can accurately distinguish lymphoma from other disorders are urgently needed, particularly in immunocompromised patients. In this study, we developed a new diagnostic nanoparticle platform for CNS lymphoma consisting of SPIONs loaded liposomes conjugated with anti-CD20 (RTX). Liposomal RTX may also exhibit activity against CNS lymphoma, although preclinical evaluations of its efficacy are still being investigated.

A previous study has evaluated ferumoxytol (Feraheme), an iron oxide nanoparticle, as 391 an MRI contrast agent for primary CNS lymphoma and CNS inflammatory disorders [29]. 392 393 From the immunofluorescence and flow cytometric results herein which demonstrate higher specificity of anti-CD20-liposome-SPIONs for detection of lymphoma cells over classically 394 395 used coated SPIONs, and the ability of anti-CD20-liposome-SPIONs, despite their large size, 396 to cross the blood-brain barrier into lymphoma xenografts, it is possible that conjugation of anti-CD20 as a targeting moiety in the liposome-SPION complex will result in greater 397 specificity for lymphoma detection by MRI than is possible in other contrast agents (such as 398 399 gadolinium and ferumoxytol). Accordingly, anti-CD20-liposome-SPIONs may serve as a

```
401 lymphoma.
```


402

403	1.	Behin, A., et al., <i>Primary brain tumours in adults.</i> The Lancet, 2003. <b>361</b> (9354): p. 323-331.
404	2.	Subsai, K., et al., Neurological complications in AIDS patients receiving HAART: a 2-year
405		retrospective study. European journal of neurology, 2006. <b>13</b> (3): p. 233-239.
406	3.	Olson, J.E., et al., The continuing increase in the incidence of primary central nervous system
407		non-Hodgkin lymphoma. Cancer, 2002. <b>95</b> (7): p. 1504-1510.
408	4.	Tun, H.W., et al., Pathway analysis of primary central nervous system lymphoma. Blood,
409		2008. <b>111</b> (6): p. 3200-3210.
410	5.	Batchelor, T. and J.S. Loeffler, Primary CNS lymphoma. Journal of Clinical Oncology, 2006.
411		<b>24</b> (8): p. 1281-1288.
412	6.	Birnbaum, T., et al., Successful long-term control of lymphomatous meningitis with
413		intraventricular rituximab. Journal of Clinical Neuroscience, 2014. <b>21</b> (2): p. 356-358.
414	7.	Gerstner, E.R., et al., Long-term outcome in PCNSL patients treated with high-dose
415		methotrexate and deferred radiation. Neurology, 2008. <b>70</b> (5): p. 401-402.
416	8.	Batchelor, T., et al., Rituximab monotherapy for patients with recurrent primary CNS
417		<i>lymphoma.</i> Neurology, 2011. <b>76</b> (10): p. 929-930.
418	9.	Bicker, J., et al., Blood-brain barrier models and their relevance for a successful development
419		of CNS drug delivery systems: a review. European Journal of Pharmaceutics and
420		Biopharmaceutics, 2014. 87(3): p. 409-432.
421	10.	Gribkoff, V.K. and L.K. Kaczmarek, The Need for New Approaches in CNS Drug Discovery: Why
422		Drugs Have Failed, and What Can Be Done to Improve Outcomes. Neuropharmacology, 2016.
423	11.	Kreuter, J., Nanoparticulate systems for brain delivery of drugs. Advanced drug delivery
424		reviews, 2001. <b>47</b> (1): p. 65-81.
425	12.	Al-Jamal, W.T. and K. Kostarelos, <i>Liposomes: from a clinically established drug delivery</i>
426		system to a nanoparticle platform for theranostic nanomedicine. Accounts of chemical
427	40	research, 2011. <b>44</b> (10): p. 1094-1104.
428	13.	Chen, HP., et al., A novel micelle-forming material used for preparing a theranostic vehicle
429		<i>exhibiting enhanced in vivo therapeutic efficacy.</i> Journal of medicinal chemistry, 2015. <b>58</b> (9):
430	1.4	p. 3704-3719.
431	14.	Luong, D., et al., Polyvalent Folate-Dendrimer-Coated Iron Oxide Theranostic Nanoparticles
432		for Simultaneous Magnetic Resonance Imaging and Precise Cancer Cell Targeting. Biomacromolecules, 2017.
433 434	15.	Luchetti, A., et al., Monoclonal antibodies conjugated with superparamagnetic iron oxide
434 435	15.	particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
435		Molecular imaging, 2012. <b>11</b> (2): p. 7290.2011. 00032.
430	16.	Ramos-Cabrer, P. and F. Campos, <i>Liposomes and nanotechnology in drug development: focus</i>
438	10.	on neurological targets. Int J Nanomedicine, 2013. 8: p. 951-960.
439	17.	Adibhatla, R.M., J. Hatcher, and K. Tureyen, <i>CDP-choline liposomes provide significant</i>
440	17.	<i>reduction in infarction over free CDP-choline in stroke.</i> Brain research, 2005. <b>1058</b> (1): p. 193-
441		197.
442	18.	Ramos-Cabrer, P., et al., Serial MRI study of the enhanced therapeutic effects of liposome-
443	_0.	encapsulated citicoline in cerebral ischemia. International journal of pharmaceutics, 2011.
444		<b>405</b> (1): p. 228-233.
445	19.	Strehl, C., et al., Effects of PVA-coated nanoparticles on human T helper cell activity.
446		Toxicology letters, 2016. <b>245</b> : p. 52-58.

- 447 20. Imamura, S., et al., *The blood–brain barrier permeability of geissoschizine methyl ether in*448 Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan.
  449 Cellular and molecular neurobiology, 2011. **31**(5): p. 787-793.
- 450 21. Chastellain, M., et al., Superparamagnetic Silica-Iron Oxide Nanocomposites for Application
  451 in Hyperthermia. Advanced Engineering Materials, 2004. 6(4): p. 235-241.
- 452 22. Kronberg, B., et al., *Preparation and evaluation of sterically stabilized liposomes: colloidal*453 *stability, serum stability, macrophage uptake, and toxicity.* Journal of pharmaceutical
  454 sciences, 1990. **79**(8): p. 667-671.
- 455 23. Wagner, S., et al., Uptake mechanism of ApoE-modified nanoparticles on brain capillary
  456 endothelial cells as a blood-brain barrier model. PloS one, 2012. 7(3): p. e32568.
- 457 24. Kayal, S. and R. Ramanujan, *Doxorubicin loaded PVA coated iron oxide nanoparticles for targeted drug delivery*. Materials Science and Engineering: C, 2010. **30**(3): p. 484-490.
- 459 25. Rho, W.-Y., et al., *Facile synthesis of monodispersed silica-coated magnetic nanoparticles.*460 Journal of Industrial and Engineering Chemistry, 2014. **20**(5): p. 2646-2649.
- 461 26. Wu, W., et al., *Recent progress on magnetic iron oxide nanoparticles: synthesis, surface*462 *functional strategies and biomedical applications.* Science and technology of advanced
  463 materials, 2015. 16(2): p. 023501.
- 464 27. Deans, J.P., H. Li, and M.J. Polyak, *CD20-mediated apoptosis: signalling through lipid rafts.*465 Immunology, 2002. **107**(2): p. 176-182.
- Taylor, R.P. and M.A. Lindorfer, *Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies.* Molecular pharmacology,
  2014. 86(5): p. 485-491.
- 469 29. Farrell, B.T., et al., Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and
  470 PCNSL. Neurology, 2013. 81(3): p. 256-263.

471

# Fig. 1.



**Figure 3**. Morphology of liposome was magnified by Transmission Election Microscopy. a) SPIONs-PVA, b) and c) = bare liposome, d) and e) = SPIONs-PVA loaded liposome at 12,000 and 40,000 magnification, respectively.


JEM-210

200 nm

# Table 1 Physicochemical characterization of liposomes

	%w/w	Size (nm)		PDI		Zeta potential (mV)		% EE of
Formulation		w/o SPIONs- PVA	w/t SPIONs- PVA	w/o SPIONs- PVA	w/t SPIONs- PVA	w/o SPIONs- PVA	w/t SPIONs- PVA	SPIONs- PVA
Lip (liposome)	100	141.9 ± 1.0	129.9 ± 5.6	$0.1 \pm 0.1$	0.3 ± 0.0	-0.1 ± 0.0	-2.3 ± 0.1	30.0 ± 4.1
Lip/PEG	90:10	169.7 ± 11.3	140.5 ± 16.2	$0.1 \pm 0.0$	0.3 ± 0.0	-2.3 ± 0.3	-5.1 ± 0.7	27.3 ± 3.3
Lip/Tween80	90:10	161.0 ± 12.6	123.8 ± 19.5	0.2 ± 0.1	0.3 ± 0.1	-0.3 ± 0.0	-2.7 ± 0.4	41.4 ± 0.0
Lip/PEG/ Tween80	80:10:10	157.2 ± 9.1	136.4 ± 4.1	0.2 ± 0.0	0.2 ± 0.0	-2.2 ± 0.2	-5.6 ± 0.7	45.6 ± 8.2
Lip/PEG/ Tween80/Rituximab	79:10:10:1	182.0 ± 6.3	158.2 ± 13.3	0.2 ± 0.0	0.3 ± 0.0	-7.2 ± 0.4	-9.0 ± 0.1	44.6 ± 3.4

# Fig. 2. MTT assay of liposome and SPIONs-PVA –loaded liposome




# Table 2 stability of liposomes

Storage period	Lip		• • •	en80/SPIONs- /A	Lip/PEG/Tween80/SPIONs- PVA/Rituximab		
	4 °C	25 °C	4 °C	25 °C	4 °C	25 °C	
Size (nm)							
1 m	123.5 ± 10.1	156.8 ± 2.7	182.4 ± 16.3	167.9 ± 24.5	152.5 ± 30.0	159.2 ± 14.7	
3 m	254.6 ± 8.1	227.1 ± 1.2	168.1 ± 7.9	244.7 ± 6.9	229.4 ± 5.5	285.7 ±12.7	
4 m	313.0 ± 16.9	379.7 ± 6.5	215.0 ± 19.5	242.0 ± 1.4	233.3 ± 8.0	236.4 ± 5.5	
ζ(mV)							
1 m	-3.6 ± 0.0	-2.6 ± 0.2	-2.1 ± 0.4	-2.9 ± 0.2	-2.6 ± 0.0	-2.1 ± 0.0	
3 m	-1.6 ± 0.2	-2.6 ± 0.0	$-1.4 \pm 0.0$	-2.1 ± 0.0	-1.5 ± 0.1	-2.0 ± 0.1	
4 m	-5.6 ± 0.7	-32.6 ± 0.1	-5.6 ± 0.4	-28.6 ± 0.7	-8.1 ± 2.0	-27.1 ± 1.1	
PDI							
1 m	$0.2 \pm 0.0$	0.2 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	$0.4 \pm 0.1$	$0.4 \pm 0.0$	
3 m	0.2 ± 0.0	0.2 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	$0.3 \pm 0.0$	
4 m	0.4 ± 0.0	0.5 ± 0.2	0.3 ± 0.0	0.2 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	

Fig. 3

Magnetization (emu/g)




samples	Saturation magnetization (emu/g)
Lip	0.0
Lip/PEG/SPIONs-PVA	0.3
Lip/PEG/Tween80/SPIONs-PVA	0.3
Lip/PEG/Tween80/SPIONs-PVA/Rituximab	0.4
SPIONs-PVA (0.5 mg/ml)	1.5
Naked SPIONs	28.9


# Fig. 4a

### Z138C

## Lip/PEG/Tween80/SPIONs-PVA




## Lip/PEG/Tween80/SPIONs-PVA/Rituximab




# Fig. 4b

## Granta


## Lip/PEG/Tween80/SPIONs-PVA



### Lip/PEG/Tween80/SPIONs-PVA/Rituximab








#### Red: cell control

Black: cell + Lip/PEG/Tween80/SPIONs-PVA Blue: cell +Lip/PEG/Tween80/SPIONs-PVA/RTX


# Dil dye

## Fig. 6a



Annexin V-FITC

Fig. 6b



Annexin V-FITC

Fig. 7




Fig. 8

## Therapeutic effect

